Alopecia Areata
Conditions
Brief summary
The efficacy of two intralesional treatment modalities for alopecia areata will be determined. Thirty patients over the age of 6 with the diagnosis of alopecia areata on the scalp, with an extension of less than 50%, will be included. A comparison will be made between the effectiveness of intralesional Triamcinolone (standard first-line treatment) and intralesional Candida albicans antigen, with serial clinical and trichoscopic pictures at follow-up to evaluate the clinical response and associated adverse effects.
Interventions
DRUGCandida Albicans Antigen Injection
subcutaneous administration of Candida albicans antigen
Sponsors
Universidad Autonoma de Nuevo Leon
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
6 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosis of alopecia areata * SALT score of less than 50% extension * Has not received any topical or systemic treatment in the last month * Signed informed consent
Exclusion criteria
* Any skin condition on the scalp (infectious, inflammatory or neoplastic) that could modify the clinical of trichoscopic features * Pregnancy or breast-feeding * Patients in medications that could cause hair loss as side-effects
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Treatment response | 5 months | porcentage of hair growth determined by SALT score |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Side effects | 5 months | Side effects associated to the treatment |
Countries
Mexico
Contacts
Primary ContactErika Alba-Rojas, MD
Outcome results
None listed